Trial0

Clinical trial · NCT07274397 · RECRUITING · NA

Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma

Sponsor: Beta Emitting Accurate Monitored Systems

Summary

This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma. The study also seeks to validate specific nuclear imaging parameters for better detection of residual tumor tissue compared to standard gadolinium-enhanced MRI. The main objectives are to determine whether early PET-MRI within 48 hours post-surgery is feasible, to assess potential side effects related to imaging procedures, and to explore if PET parameters such as SUVmax, metabolic volume, and tumor-to-striatum ratio can improve the detection of tumor residue. A total of 15 patients will be included at a single site in France. Participants will undergo PET-MRI using 18F-DOPA and gadolinium, and will be monitored for radiation exposure and possible adverse events up to 24 hours after imaging.

Interventions

  • Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium · DIAGNOSTIC_TEST

    This intervention consists of a combined brain PET-MRI imaging session performed within 48 hours after surgical resection of a suspected glioblastoma. The PET scan uses 18F-DOPA as the radiotracer, administered intravenously at a dose of 2 MBq/kg, with static brain acquisition starting immediately post-injection. The MRI includes standard sequences and gadolinium-based contrast-enhanced imaging. The goal is to assess the feasibility and safety of this early post-operative imaging procedure, and to validate imaging parameters for the detection of residual tumor. Radiation dosimetry and potential adverse events related to imaging agents will be monitored.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* First resection for a suspected glioblastoma in the past 72h
* Signed informed consent

non-inclusion Criteria:

* Deprived of liberty or under legal protection (e.g, guardianship, trusteeship)
* Patients under 18 years old
* Absence of social security cover
* Pregnancy
* Emergency procedure
* Contraindication to brain MRI, including claustrophobia
* Contraindication to radiotracers or gadolinium injection
* Preoperative cognitive impairment impeding patient information

Exclusion criteria :

* Any postoperative behavioral disorders or medical condition or symptom impeding the completion of brain imaging
* Postoperative medical dependency impeding the patient transfer to the nuclear medicine department (including, but not limited to, invasive ventilation, need for external ventricular drainage…)
* Postoperative histological diagnosis different from glioblastoma

Sites (1)

  • Hôpital Henri Mondor - Université Paris-Est Créteil (UPEC), Créteil, France · RECRUITING

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-06-08.